Chrystal U Louis
Overview
Explore the profile of Chrystal U Louis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
3152
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li C, Sharma S, Heczey A, Woods M, Steffin D, Louis C, et al.
Nat Med
. 2025 Feb;
PMID: 39962287
In a phase 1 clinical trial open to accrual from 2004 to 2009, we treated children with neuroblastoma with Epstein-Barr virus (EBV)-specific T lymphocytes and CD3-activated T cells-each expressing chimeric...
2.
Gupta A, Azul M, Bhoopalan S, Abraham A, Bertaina A, Bidgoli A, et al.
Cytotherapy
. 2024 Jul;
26(11):1411-1420.
PMID: 38970612
Genetic manipulation of hematopoietic stem cells (HSCs) is being developed as a therapeutic strategy for several inherited disorders. This field is rapidly evolving with several novel tools and techniques being...
3.
Che-Hsing L, Sharma S, Heczey A, Steffin D, Louis C, Grilley B, et al.
Res Sq
. 2024 Apr;
PMID: 38659815
We report long-term outcomes up to 18 years of a clinical trial treating children with neuroblastoma with EBV-specific T lymphocytes and CD3-activated T cells - each expressing a first-generation chimeric...
4.
Ecker D, Aiello C, Arron J, Bennett C, Bernard A, Breakefield X, et al.
Nat Rev Drug Discov
. 2024 Feb;
23(5):321-322.
PMID: 38409339
No abstract available.
5.
Tomlinson B, de Lima M, Cogle C, Thompson M, Grinblatt D, Pollyea D, et al.
Transplant Cell Ther
. 2023 Apr;
29(7):460.e1-460.e9.
PMID: 37086851
Hematopoietic stem cell transplantation (HCT) is indicated for patients with higher-risk (HR) myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Age, performance status, patient frailty, comorbidities, and nonclinical factors (eg,...
6.
Pollyea D, George T, Abedi M, Bejar R, Cogle C, Foucar K, et al.
EJHaem
. 2022 Jul;
1(1):58-68.
PMID: 35847712
Diagnostic and molecular genetic testing are key in advancing the treatment of acute myeloid leukemia (AML), yet little is known about testing patterns outside of clinical trials, especially in older...
7.
Von Hoff D, Cridebring D, Tian O, Han H, Bhore R, Franco T, et al.
Oncologist
. 2020 Dec;
26(4):e704-e709.
PMID: 33345430
Background: We examined overall survival (OS) outcomes based on plasma 25-hydroxyvitamin D [25(OH)D] levels in this post hoc analysis of the phase III MPACT trial of metastatic pancreatic cancer. Materials...
8.
Patel J, Abedi M, Cogle C, Erba H, Foucar K, Garcia-Manero G, et al.
Int J Lab Hematol
. 2020 Nov;
43(3):426-432.
PMID: 33220019
Introduction: The presence of ring sideroblasts (RS) and mutation of the SF3B1 gene are diagnostic of lower-risk (LR) myelodysplastic syndromes (MDS) and are correlated with favorable outcomes. However, information on...
9.
Wainberg Z, Hochster H, Kim E, George B, Kaylan A, Chiorean E, et al.
Clin Cancer Res
. 2020 Jun;
26(18):4814-4822.
PMID: 32554514
Purpose: Assess safety and efficacy of nivolumab plus -paclitaxel and gemcitabine in patients with locally advanced/metastatic pancreatic cancer in a two-part, open-label, phase I trial. Patients And Methods: Fifty chemotherapy-naive...
10.
Goldstein D, Von Hoff D, Chiorean E, Reni M, Tabernero J, Ramanathan R, et al.
Pancreas
. 2020 Jun;
49(6):744-750.
PMID: 32541630
Objectives: This analysis investigated nomogram use to evaluate metastatic pancreatic cancer prognosis. Methods: Thirty-four baseline factors were examined in the Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) (nab-paclitaxel plus gemcitabine vs...